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Background. To compare the frequency of adverse events of thermal microwave (MWA) and radiofrequency abla-
tion (RFA) with non-thermal irreversible electroporation (IRE) in percutaneous ablation of hepatocellular carcinoma 
(HCC).
Patients and methods. We retrospectively analyzed 117 MWA/RFA and 47 IRE procedures (one tumor treated 
per procedure; 144 men and 20 women; median age, 66 years) regarding adverse events, duration of hospital and 
intensive care unit (ICU) stays and occurrence of a post-ablation syndrome. Complications were classified according 
to the Clavien & Dindo classification system.
Results. 70.1% of the RFA/MWA and 63.8% of the IRE procedures were performed without complications. Grade I and 
II complications (any deviation from the normal postinterventional course, e.g., analgesics) occurred in 26.5% (31/117) 
of MWA/RFA and 34.0% (16/47) of IRE procedures. Grade III and IV (major) complications occurred in 2.6% (3/117) of 
MWA/RFA and 2.1% (1/47) of IRE procedures. There was no significant difference in the frequency of complications 
(p = 0.864), duration of hospital and ICU stay and the occurrence of a post-ablation syndrome between the two groups.
Conclusions. Our results suggest that thermal (MWA and RFA) and non-thermal IRE ablation of malignant liver tumors 
have comparable complication rates despite the higher number of punctures and the lack of track cauterization in 
IRE.
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Introduction
Percutaneous ablation of HCC under imaging con-
trol in focal tumor therapy has gained in impor-
tance in recent years. Besides surgical resection and 
liver transplantation, ablation is one of three cura-
tive therapies for the treatment of hepatocellular 
carcinoma (HCC).1 Most ablation techniques are 
so-called thermal methods, which are based on the 
generation of coagulation necrosis by heat. While 
radiofrequency ablation (RFA) and microwave ab-
lation (MWA) are among these thermal techniques, 
irreversible electroporation (IRE), along with other 
therapies such as electrochemotherapy (ECT), is a 
non-thermal method for destruction of tumor tis-
sue.2,3
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IRE uses ultrashort but strong electric fields to 
create nanopores in the cell membrane, thereby 
disturbing the cellular homeostasis and subse-
quently causing cell death by apoptosis.4 IRE is 
not affected by the “heat-sink-effect”5-9 and can 
be applied in close proximity to temperature-
sensitive structures such as bile ducts. Therefore, 
IRE is a useful technique in particular for central 
liver tumors in the vicinity of larger vessels and 
bile ducts.2 However, IRE has the theoretical dis-
advantage compared to thermal procedures that 
up to six electrodes have to be put in place (i.e., 
multiple trauma by puncture), and the puncture 
channel cannot be cauterized. First studies with 
limited number of cases have described possible 
complications after IRE, such as bleeding, portal 
vein thrombosis, infections, needle tract seeding 
and bile duct injuries.10-12 However, larger cohort 
studies and systematic meta-analysis involving 
more than 10,000 patients exist only for thermal 
ablation methods.13,14 To the best of our knowl-
edge, no work systematically compares so far the 
complication rates between the thermal methods 
RFA/MWA and IRE.
This study aims to identify possible differences 
between complication rates and the morbidity of 
patients following thermal and non-thermal abla-
tion procedures in order to guide optimal therapy 
decisions in the future.
Patients and methods
Study design and participant selection
The retrospective single-center study was ap-
proved by the Ethics Committee of the University 
Regensburg. It was carried out in accordance with 
the relevant guidelines and regulations, and in-
formed consent was waived.
The clinical reports of all patients who under-
went percutaneous tumor ablation at our interven-
tional oncology center between 07/2010 and 05/2017 
were reviewed. The indication for the percutane-
ous ablation was based exclusively on clinical cri-
teria. Ablations in which more than one tumor was 
treated were excluded from further examination to 
ensure comparability between the groups. 
 The following parameters were assessed for 
both groups:
●  intervention time
● length of hospital stay
●  occurrence and length of intensive care unit 
(ICU) stay
● clinical course post intervention.
Ablation procedures and imaging
All procedures were performed under general an-
esthesia and percutaneously under CT fluoroscopy 
guidance (CAREVision, SOMATOM Sensation 16, 
Siemens Healthcare).
Hematologic management was performed ac-
cording to the consensus guidelines of the society 
of interventional radiology for procedures with a 
moderate risk of bleeding.15 In summary, the INR 
was corrected to < 1.5 and the aPTT to values > 1.5. 
If the platelets were less than 50,000 per ml, a trans-
fusion with platelet concentrates was performed. 
Clopidogrel was paused 5 days before ablation. For 
low molecular weight heparins, the last adminis-
tration was suspended before the intervention. 
IRE procedures were performed with the 
NanoKnife® System (Angiodynamics®) using 
up to six 19G electrodes. The parameters of IRE 
ablation were as follows: voltage, 1650 to 3000 V; 
pulse length, 90 μs; pulses per cycle, 70. Microwave 
ablation was carried out using the Acculis micro-
wave tissue ablation system and a 14G applica-
tor (AngioDynamics, Latham, NY, USA), which 
operates at 2.45 GHz with a maximum power 
output of 140 W. For radiofrequency ablation, 
the StarBurst©, RITA©, 1500X ablation system 
(AngioDynamics, Latham, NY, USA) with monop-
olar perfused 14G electrodes (StarBurst©, Talon 
Semi-Flex, AngioDynamics, Latham, NY, USA) 
was employed.
After probe placement for the ablation proce-
dure, the parameters were adjusted depending on 
tumor size with the aim to gain a preferable safety 
margin of 1 cm.
The first follow-up imaging was routinely con-
ducted on the first working day after the ablation 
through an abdominal CT and magnetic resonance 
imaging (MRI). Laboratory tests and physical ex-
aminations were continued until discharge of the 
patient.
Complications
Complications were documented for each ablation 
session by evaluating medical records and radio-
logic images. Since during the post-interventional 
clinical course the patients were admitted on a sur-
gical ward, post-interventional complications were 
defined according to the “Classification of Surgical 
Complications” according to Clavien & Dindo”16, 
which allows a detailed insight into the grade of 
recorded events and even small treatment adjust-
ments are included.
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Post-ablation syndrome
The post-ablation syndrome is characterized by fe-
ver or flu-like symptoms following ablation treat-
ment.17 In addition, nausea, vomiting, malaise and 
body aches have been described.18 However, in 
most cases the symptoms are per se self-limiting 
under purely symptom-oriented therapy.19 In rare 
cases after treatment of large tumor areas, the post-
ablation syndrome can last up to three weeks.19 By 
contrast, persistent or later onset of fever may indi-
cate a simultaneous infection or abscess.17 
Statistical analysis
All statistical analyses were performed with IBM 
SPSS Statistics (version 24, Chicago, IL, USA) and 
R 3.2.1. The data are presented as the median with 
the interquartile range (IQR) if not stated otherwise. 
The non-parametric Mann-Whitney test was used to 
analyze patients and tumor characteristics, the inter-
vention time, and the length of the hospital and ICU 
stay. We used the Chi-Square Test of independence 
for comparing the observed frequencies of events 
(ICU-stay (y/n), post-ablation syndrome (y/n)) and 
examined trend of complication grades between 
both groups using the Cochran-Armitage test for 
trend. The Fisher’s exact test was used to compare 
the in-house mortality. All tests were two-sided, and 
values of p < 0.05 indicated a significant difference.
Results
Patient and tumor characteristics
In this study, 117 patients with HCC were treated 
with thermal ablations (microwave and radiof-
requency ablation) and 47 with irreversible elec-
troporation (IRE). Of the 164 patients, 31 (18.9%) 
were listed for liver transplantation and ablation 
was performed for bridging. The patient and lesion 
aspects are summarized in Table 1.
A tumor was defined as close to a major vessel if 
the distance to a vessel with a diameter > 5 mm was 
less than 5 mm. A tumor was defined as peripheral 
if the maximum distance between all parts of the 
tumor and the liver capsule was 3 cm.
Intervention time
The median intervention duration of all interven-
tions was 113 min (IQR 96) (Table 2). A significant 
difference (p = 0.047) was observed between the 
duration of thermal ablation (103, IQR 103) and ir-
reversible electroporation (142, IQR 88).
Hospital and ICU-stay
Duration of hospital stays ranged between 2 and 
50 days for thermal ablation and between 2 and 20 
days for irreversible electroporation, with a medi-
an of 5 days (IQR 4) for both types of interventions 
(p = 0.752). There was no significant difference be-
tween thermal ablation and irreversible electropo-
ration regarding the frequencies (12.0% (14/117) 
vs. 6.4% (3/47), p = 0.302) as well as the length of 
ICU-stays with a median ICU stay of 4 days (IQR 4) 
TABLE 1. Patient and tumor characteristics of the RFA/MWA and IRE group
RFA/MWA (n = 117) IRE (n = 47) p-value
Male, n (%) 98 (83.8) 46 (97.9) 0.013
Age
 median (IQR) 66 (14) 71 (15) 0.239
 range 45 - 82 45 - 83
Child-Pugh-Score, n (%) 0.892
 A 76 (65.0) 30 (63.8)
 B 41 (35.0) 17 (36.2)
BCLC, n (%) 0.412
 A 68 (58.1) 24 (51.1)
 B 49 (41.9) 23 (48.9)
Tumor size, mm (mean +- SD) 22 +- 9 20 +- 8 0.186
Liver periphery, n (%) 85 (72.6) 25 (53.2) 0.017
Close to a major vessel, n (%) 19 (16.2) 21 (44.7) ≤ 0.001
BCLC = Barcelona Clinic Liver Cancer staging system; IQR = interquartile range; IRE = non-thermal 
irreversible electroporation; RFA/MWA = radiofrequency ablation / microwave ablation
TABLE 2. Intervention durations, hospital and intensive care unit (ICU) stay, 
occurrence of post-ablation syndrome for thermal ablation and non-thermal 
irreversible electroporation (IRE)
All (164) RFA/MWA(n = 117)
IRE
(n = 47) p-vale
Intervention duration, minutes 
(IQR) 113 (96) 103 (103) 142 (88) 0.031
Hospital Stay, days
 days, median (IQR) 5 (4) 5 (4) 5 (4) 0.752
 days, range 2-50 2-50 2-20
ICU Stay, n (%) 17 (10) 14 (12) 3 (6) 0.302
 days, median (IQR) 4 (5) 4 (4) 6 (-) 0.222
 days, range 1-9 1-9 3-9
Post-ablation Syndrome, n (%) 28 (17) 21 (18) 7 (15) 0.607
IQR = interquartile range; RFA/MWA = radiofrequency ablation / microwave ablation
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1), HB drop after IRE with explorative laparotomy 
without intraoperatively visible bleeding source 
(n = 1). There was one grade IVb complication with 
partial main portal vein thrombosis after MWA fol-
lowed by an ICU stay and multi-organ dysfunction 
(Figure 2).
Primary efficacy, i.e. the percentage of target tu-
mors successful eradicated in the 6-week follow-up 





TABLE 3. Clavien & Dindo classification system with the corresponding number of events in the thermal and non-thermal irreversible electroporation 
(IRE) groups





(n = 47)Grade Description
0 No complication No complication 82 (70.1%) 30 (63.8%)
I 
Any deviation from the normal postinterventional course without the need for 
pharmacological treatment or surgical, endoscopic and radiological interventions
(Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, 
diuretics, and electrolytes, and physiotherapy. This grade also includes wound 
infections opened at the bedside)
Mild 11 (9.4%) 9 (19.1%)
II Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included. Moderate
20 (17.1%) 7 (14.9%)
III requiring surgical, endoscopic or radiological intervention
 IIIa intervention not under general anesthesia Moderate 1 (0.9%) 0
 IIIb intervention under general anesthesia Severe 1 (0.9%) 1 (2.1%)
IV Life-threatening complication (including CNS complications) requiring IC/ICU- management
 IVa single organ dysfunction (including dialysis) Severe/Life-threatening 0 0
 IVb multi organ dysfunction Life-threatening 1 (0.9%) 0
V Death of a patient Patient death 1 (0.9%) 0
ICU = intensive care unit; IQR = interquartile range; RFA/MWA = radiofrequency ablation / microwave ablation; SIR = Society of Interventional Radiology
FIGURE 1. 68-year-old female patient with active bleeding (A) on the dorsal side 
of the left lobe of the liver (*) immediately after RFA and perisplenic hematoma 
(#). Diagnostic angiography (B) immediately after the RFA did not show any active 
arterial bleeding. The patient was then monitored on a normal ward, and the 
bleeding ceased without further intervention.
for patients treated with thermal ablation versus 6 
days for patients treated with IRE (p = 0.222).
Clinical course post intervention
In 17.1% of the treatments, a post-ablation syn-
drome occurred during the post-interventional 
clinical course. Significant differences between 
thermal ablation (17.9%) and IRE (14.9%) were not 
observed (p = 0.607). 
68.3% of the procedures were performed with-
out any complication. There was no significant dif-
ference between thermal ablation and IRE regard-
ing the occurrence and the severity of a complica-
tion (p = 0.864).
One patient died 11 days after MWA due to mul-
tiorgan failure after an accidental puncture of the 
pericardium with hemopericardium and surgical 
overstitching (Table 3). The incidence of all docu-
mented complications is listed in Table 2. The most 
common complications of grade II were: blood 
transfusions (n = 10), infections (n = 6), electrolyte 
shifts (n = 4).
Grade III complications were: bleeding after 
RFA followed by angiography without detectable 
source of bleeding and active monitoring on the 
ward (n = 1; Figure 1), pleural drainage for reactive 
pleural effusion after sub-diaphragmatic MWA (n = 
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Discussion
Hepatocellular carcinoma (HCC) is the world’s 
third most common cancer leading to death.20 In 
Germany, cancer of the liver and intrahepatic bile 
ducts are among the top 10 deaths from cancer.21 
At the time of initial diagnosis, only 10–25% of pa-
tients represent candidates for surgery.22 
Since early detection of cancer enables better 
prognosis and longer survival, it is recommended 
that people with the appropriate risk profile be 
screened for HCC.23 According to EASL guide-
lines, half-yearly ultrasound examinations should 
be performed in patients with cirrhosis of the liver 
in stages Child-A and Child-B as well as in pa-
tients in stage Child-C if they are eligible for liver 
transplantation. In the case of abnormalities, ad-
ditional contrast-enhanced imaging should be per-
formed.24,25 
In recent years, such observation strategies of 
patients with an increased risk-profile led to an ear-
lier diagnosis of the disease and detection of HCCs 
at earlier stages. In addition to the higher chance 
of therapeutic response, early-stage patients also 
benefit from a broader range of different treatment 
options.26 
Therapeutic options for hepatocellular carci-
noma include surgical resection, liver transplanta-
tion, locoregional treatments, and chemotherapy. 
The final treatment decision depends mainly on 
the tumor stage, the patient performance status, 
and the functional liver reserve and requires a mul-
tidisciplinary approach.26 
Which therapy is used in the respective case de-
pends in particular on how far the disease has pro-
gressed at the time of diagnosis and in what condi-
tion the liver is. The patient’s age and the general 
state of health are also considered when choosing 
a treatment method.27-29 The effectiveness of the lo-
cal-ablative therapy procedures could be proven in 
numerous studies of liver cancer up to a size of 3-5 
cm. The use of local ablative procedures does not 
exclude subsequent surgical therapy. Furthermore, 
local-ablative procedures are often used to bridge 
waiting time until liver transplantation.
Irreversible Electroporation (IRE) is a novel, 
minimally invasive technique for the targeted de-
struction of cells by strong, locally limited electrical 
fields. Experience to date suggests that, in contrast 
to other local treatment methods, this technique 
explicitly targets the tumor cells. Other structures 
such as blood vessels and bile ducts are not per-
manently damaged. Potential disadvantages of the 
IRE are an increased risk of bleeding, due to the 
necessity of placing up to 6 electrodes in the liver 
and the lack of the possibility to cauterize the punc-
ture channel.
Considering ongoing discussions which therapy 
should be used in respective patients, we have ana-
lyzed thermal ablation and irreversible electropo-
ration ablation of HCC in the context of postinter-
ventional morbidity.
In our patient cohort, the treatment decision was 
made by the local tumor board consisting of at least 
one certified hepatologist, oncologist, intervention 
radiologist and a highly qualified hepatobiliary 
surgeon with experiences in liver transplantation.
The incidence rates of the post-ablation syn-
drome vary significantly between studies. For ex-
ample, in a prospective study of 54 patients treated 
with microwave ablation in liver tumors, 60% de-
veloped post-ablation syndrome.30 All in all, post-
ablation syndrome is seen in about one-third of 
patients after thermal ablation18,31. In our study, 
17% of the patients had a post-ablation syndrome 
during the post-interventional clinical course with 
no differences between thermal and non-thermal 
ablations.
In this retrospective analysis, we report a sys-
tematical comparison between the complication 
rates of thermal ablation and IRE for a large patient 
collective.
Livraghi et al. reported six deaths (0.3%) and 50 
other serious complications (2.2%) in a multicenter 
study in which more than 3,500 liver tumors were 
treated in 2,320 patients by thermal ablation.32 
Frühling et al. reported in a single-center study a 
minor complication rate of 20% (6 out of 30) and 
one (3.3%) major complication (bile duct dilata-
A B
*
FIGURE 2. 57-year-old male patient with partial thrombosis (*) of the main portal 
vein one day after microwave ablation (B). (A) Pre-interventional CT scan without 
visible thrombosis. Anticoagulation led to the regression of thrombosis without any 
necessary intervention.
B
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tion and stricture of the portal vein and bile duct) 
for IRE33, while Zeng et al. reports an event rate of 
71.4% of minor and 7.1% of major complications 
for a small patient collective (n = 14).34
Comparing our results to previous studies we 
report a comparable rate of major complications 
(Grade III-V) for each procedure. However, num-
bers of minor complications (Grade I and II) are 
higher compared to previously reported studies. 
Of note, we used the “Classification of Surgical 
Complications” according to Clavien & Dindo”.16 
In comparison to the standardized grading system 
of the Society of Interventional Radiology (SIR)19,35, 
this classification scheme offers a more detailed in-
sight into the grade of recorded complications and 
especially includes events as Grade I complications 
that are not included in the SIR-classification. The 
SIR-classification only differentiates between ma-
jor and minor complications; however, the classi-
fication reported in this study distinguishes five 
grades of complications, ranging from minor vari-
ation from the normal postinterventional course to 
the death of a patient.
Despite the retrospective collection of data, we 
were able to demonstrate that there was no sig-
nificant difference in the occurrence as well as 
the grade of complications regarding the use of 
thermal versus non-thermal ablation, indicating 
a noninferiority of IRE in comparison to thermal 
ablation techniques. This is all the more remark-
able because the tumors treated with IRE were sig-
nificantly more frequently close to a major vessel 
and thus more complication-prone. In contrast, the 
tumors treated with RFA/MWA were significantly 
more frequently located in the easily accessible pe-
riphery.
We propose that the fear of a higher complica-
tion rate should not interfere with the treatment 
decision regarding thermal versus non-thermal 
ablation.
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